



US DEPARTMENT OF DEFENSE
BLAST INJURY RESEARCH PROGRAM
COORDINATING OFFICE

Transplants and Burn Injury Treatment

Treatment to Limit Burn Injury Progression

Burn injuries often become larger in the two to three days following injury, resulting in a higher risk of scarring, contractures, infection, disability, and possibly mortality from more serious wounds. Currently there is no treatment to stop this process. With funding from USAMMDA and AFIRM, investigators at Synedgen Inc. are developing and evaluating a treatment to prevent burn injury progression. Synedgen's product has been demonstrated in vivo and in vitro to reduce inflammation and increase healing in dermal wounds. In a porcine burn model, the treatment reduced inflammation and fibrosis. In the current effort, Synedgen aims to improve the healing rate and to reduce inflammation and fibrotic scar formation in burns. The investigators are completing preclinical studies necessary to support an Investigational New Drug application to the FDA. A clinical trial is expected in the next two to three years.